Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-18
2000-01-25
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
562575, 570123, 514724, A61K 3805
Patent
active
060178876
ABSTRACT:
Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4472305 (1984-09-01), Hansen et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4701407 (1987-10-01), Appel
patent: 4840935 (1989-06-01), Wagnon et al.
patent: 4845079 (1989-07-01), Luly
patent: 5015570 (1991-05-01), Scangos et al.
patent: 5034376 (1991-07-01), Hoover
patent: 5039511 (1991-08-01), Quay et al.
patent: 5039642 (1991-08-01), Chrobaczek et al.
patent: 5081284 (1992-01-01), Higuchi et al.
patent: 5164371 (1992-11-01), Edwards
patent: 5200339 (1993-04-01), Abraham
patent: 5213962 (1993-05-01), van Nostrandt et al.
patent: 5218100 (1993-06-01), Muller-Hill et al.
patent: 5221665 (1993-06-01), Skiles
patent: 5223633 (1993-06-01), Hoppe et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5232928 (1993-08-01), Skiles
patent: 5234814 (1993-08-01), Card et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5270165 (1993-12-01), van Nostrandt et al.
patent: 5284828 (1994-02-01), Hemmi et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5427931 (1995-06-01), Van Nostrand et al.
patent: 5430022 (1995-07-01), Hemmi et al.
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5470833 (1995-11-01), Ishikawa et al.
patent: 5496928 (1996-03-01), Ishikawa et al.
patent: 5508167 (1996-04-01), Roses et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5547841 (1996-08-01), Marrotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5612486 (1997-03-01), McConlogue et al.
English language Abstract of Japanese Pat. No. 6346722 (Dialog File 351: Derwent WPI Accession No.: 95-070275), Dec. 20, 1994.
Anderson et al, "Differential induction of immediate early gene proteins in cultured neurons by .beta.-amyloid (A.beta.): Association of c-jun with A.beta.-induced apoptosis," J. Neurochem. 65(4):1487-1498 (1995).
Asami-Odaka et al., "Long amyloid .beta.-protein secreted from wild-type human neuroblastoma IMR-32 cells," Biochemistry 34:10272-10278 (1995).
Barry et al., "Protection against mycoplasma infection using expression-library immunization," Nature 377:632-635 (1995).
Checler, "Processing of the .beta.-amyloid precursor protein and its regulation in Alzheimer's disease," J. Neurochem. 65(4):1431-1444 (1995).
Le et al, ".beta.-amyloid.sub.1-40 increases expression of .beta.-amyloid precursor protein in neuronal hybrid cells," J. Neurochem. 65(5):2373-2376 (1995).
Mahdi et al., "Protease nexin/amyloid .beta.-protein precursor inhibits factor Xa in the prothombinase complex," J. Biol. Chem. 270(40):23468-23474 (1995).
Mark et al., "Amyloid .beta.-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca.sup.2+ homeostasis and cell death," J. Neurosci. 15(9):6239-6249 (1995).
Moss et al., "Peptidometric inhibitors of herpes simplex virus ribonucleotide reductase: A new class of antiviral agents," J. Med. Chem. 38:3617-3623 (1995).
Pike et al., "Amino-terminal deletions enhance aggregation of .beta.-amyloid peptides in vitro," J. Biol. Chem. 270(41):23895-23898 (1995).
Thaisrivongs et al., "Structure-based design of novel HIV protease inhibitors: Carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors," J. Med. Chem. 38:3624-3637 (1995).
Wang et al., "A novel matrix attachment region DNA binding motif identified using a random phage peptide library," J. Biol. Chem. 270(40):23239-23242 (1995).
Xu et al., "Regulated formation of Golgi secretory vesicles containing Alzheimer's .beta.-amyloid precursor protein," J. Biol. Chem. 270(40):23243-23245 (1995).
Yoshimoto et al., "NACP, the precursor protein of the non-amyloid .beta./A4 protein (A.beta.) component of Alzheimer's disease amyloid, binds A.beta. and stimulates A.beta. aggregation," Proc. Natl. Acad. Sci. USA 92:9141-9145 (1995).
Martichonock et al., Azarine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases. J. Med. Chem. 38, 3078-3085 (1995).
Woo et al., Peptidyl aldehyde derivatives as potent and selective inhibitors of cathespin L. Bioorg. Med. Chem. Lett. 5, 1501-1504 (1995).
Angelastro, et al., "Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones," J. Med. Chem., 37:4538-4554 (1994).
Angliker, et al., "Inactivation of calpain by peptidyl fluoromethyl ketones," J. Med. Chem., 35:216-220 (1992).
Arner, et al., "1-Chloro-2,4-dinitrobenzene is an Irreversible Inhibitor of Human Thioredoxin Reductase," J. Biol. Chem., 270(8):3479-3482 (1995).
Bodanszky and Bodanszky, "I. Protecting Groups 5. The tert.Butyloxycarbonyl (Boc) Group," The Practice of Peptide Synthesis, Springer-Verlag, pp. 18-20 (1984).
Bradbury, et al., "1,2,4-Triazolo[4,3-.alpha.]pyrazine Derivatives with Human Renin Inhibitory Activity," J. Med. Chem., 33:2335-2342 (1990).
Breaux and Bender, "The binding of specific and non-specific aldehyde substrate analogs to .alpha.-chymotrypsin," FEBS Letters, 56(1):81-84 (1975).
Inoue, et al., "Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase," J. Biol. Chem., 268(8):5894-5898 (1993).
Ito, et al., "Synthetic study of peptide aldehydes," Chem. Pharm. Bull., 23(12):3106-3113 (1975).
Ito, et al., "Peptide aldehydes inhibiting chymotrypsin," Biochem. and Biophys. Res. Comm., 49(2):343-349 (1972).
Iwanowicz, et al., "Retro-binding tripeptide thrombin active-site inhibitors: Discovery, synthesis, and molecular modeling," J. Med. Chem., 37(14):2122-2124 (1994).
Kaiser, et al., "Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides," Analyt. Biochem., 34:595-598 (1970).
Kapoor, "Recent trends in the synthesis of linear peptides," J. Pharm. Sci., 59(1):1-27 (1970).
Kowall, et al., "An in vivo model for the neurodegenerative effects of .beta. amyloid and protection by substance P," Proc. Natl. Acad. Sci. USA, 88:7247-7251 (1991).
Krishnamurti, et al., "Preparation of Trifluoromethyl and Other Perfluoroalkyl Compounds with (Perfluoralkyl)trimethylsilanes," J. Org. Chem., 56:984-989 (1991).
Lai, et al., "Characterization of Sorting Signals in the .beta.-Amyloid Precursor Protein Cytoplasmic Domain," J. Biol. Chem., 270(8):3565-3573 (1995).
Lamb, et al., Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice Nature Genet., 5:22-29 (1993).
Lannfelt, et al., "Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden," Neurosci. Letters, 153:85-87 (1993).
Lannfelt, et al., "Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family," Neurosci. Letters, 168:254-256 (1994).
Lehninger, "The amino acid building blocks of proteins," Biochemistry (2d Ed.) The Molecular Basis of Cell Structure and Function, pp. 71-92.
Levy, et al., Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type, Science, 248:1124-1126 (1990).
Linderman, et al., "Unique Inhibition of a Serine Esterase," Tetrahedron Letters, 34(20):3227-3230 (1993).
Marx, "Major setback for Alzheimer's models," Science, 25:1200-1202 (1992).
Matsumoto and Fujiwara, "Abnormal and deficient pr
Albrecht Elisabeth
McDonald Ian A.
Munoz Benito
Lukton David
Seidman Stephanie L.
SIBIA Neurosciences Inc.
Tsang Cecilia J.
LandOfFree
Peptide, peptide analog and amino acid analog protease inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide, peptide analog and amino acid analog protease inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide, peptide analog and amino acid analog protease inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2315990